
Sign up to save your podcasts
Or


We love to hear from our listeners. Send us a message.
Elixirgen Therapeutics' Aki Ko joins Erin Harris to detail the company's Bobcat mRNA therapeutic and how it differs from traditional exon-skipping drugs and AAV-microdystrophin in treating DMD. Regarding delivery, Ko explains the advantage of the mRNA approach over the AAV approach.
Subscribe to the podcast!
Apple | Spotify | YouTube
Visit my website: Cell & Gene
Connect with me on LinkedIn
By Erin Harris4.9
3838 ratings
We love to hear from our listeners. Send us a message.
Elixirgen Therapeutics' Aki Ko joins Erin Harris to detail the company's Bobcat mRNA therapeutic and how it differs from traditional exon-skipping drugs and AAV-microdystrophin in treating DMD. Regarding delivery, Ko explains the advantage of the mRNA approach over the AAV approach.
Subscribe to the podcast!
Apple | Spotify | YouTube
Visit my website: Cell & Gene
Connect with me on LinkedIn

32,092 Listeners

30,687 Listeners

3,222 Listeners

2,670 Listeners

763 Listeners

181 Listeners

277 Listeners

324 Listeners

34 Listeners

2,101 Listeners

146 Listeners

19 Listeners

56 Listeners

16 Listeners

165 Listeners